Press Space to continue
Finding signal on Twitter is more difficult than it used to be. We curate the best tweets on topics like AI, startups, and product development every weekday so you can focus on what matters.
Press Space to continue
Press Space to continue
AI improves with verification loops: “the model does the eval.” We’ve seen what’s possible when this is applied to coding. What about biology? Polyphron is building a scaled tissue foundry so we can apply the same RL approach we have in digital environments to living ones. “AI is becoming increasingly capable of generating biological hypotheses, therapeutic candidates and experimental designs. But generating ideas is advancing much faster than our ability to test what those ideas will…
Today we’re announcing we’ve raised $20M in seed financing led by @QuietCapital , with participation from @GradientVC , @haystackvc and @CompoundVC and other amazing folks to build the verification layer for AI-driven biology. We are also delighted to be welcoming @vqctran who is joining us from @GoogleDeepMind as a co-founder. AI is not going to cure all diseases without a verification substrate - a scalable environment where models can test predictions and learn against living human biology. AI is becoming increasingly capable of generating biological hypotheses, therapeutic candidates and experimental designs. But generating ideas is advancing much faster than our ability to test what those ideas will actually do in human biology. Existing systems force a tradeoff: the most biologically relevant approaches are slow and expensive, while faster in vitro and computational systems often lack the fidelity needed to capture human response. Polyphron’s bet is that tissue is the fastest, cheapest, most parallelizable verification substrate that still contains the biology that matters and we believe the path to biological superintelligence runs through closed-loop interaction with these living and simulated human systems. Thank you to @axios for covering the announcement. Link to our new website in the thread.